Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook
Swedish bank Handelsbanken has reduced its share price target for Novo Nordisk by DKK 95 (USD 14.5) due to uncertainties about the pharmaceutical company's forecast for 2022, slated to be publicized on February 2.
.jpg)
by marketwire, translated by daniel pedersen
Swedish bank Handelsbanken has lowered its share price target for Novo Nordisk from DKK 745 (USD 113.5) to DKK 650 (USD 99), while the bank's recommendation remains on "hold," Handelsbanken reports in an analysis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Catalent behind Novo Nordisk's supply issues, says media
For subscribers
